Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. AMMAN PHARMACEUTICAL INDUSTRIES
WARNING LETTER
•AMMAN PHARMACEUTICAL INDUSTRIES•August 15, 2023

AMMAN PHARMACEUTICAL INDUSTRIES – FDA Warning Letter, Aug 15, 2023

Record Details

The FDA issued a Warning Letter to Amman Pharmaceutical Industries (FEI 3013501887) following an inspection from August 7-15, 2023, identifying significant Current Good Manufacturing Practice (CGMP) violations for finished pharmaceuticals, rendering their drug products adulterated.

Key violations include: 1. **Inadequate Facility and Equipment Design (21 CFR 211.42(c)(10)):** Aseptic processing areas had fundamental design flaws, such as exposed product, inadequate hopper covers, and sterile tubing contacting non-sterile surfaces, compromising aseptic conditions. 2. **Inadequate Monitoring of Aseptic Processing:** The firm failed to ensure adequate environmental monitoring, with over 50 microbial excursions observed despite claims of no issues. Data integrity breaches compromised the reliability of test results, and environmental isolate identification was insufficient. 3. **Failure to Prevent Microbiological Contamination (21 CFR 211.113(b)):** The firm shipped sterile products to the U.S. without conducting process simulations (media fills) or adequately documenting operator interventions. Poor aseptic technique and insufficient sterilization of equipment directly contacting sterile product constituents were also observed. 4. **Incomplete Laboratory Records (21 CFR 211.194(a)):** Laboratory records lacked complete and trustworthy data, with evidence of overwritten, discarded, and unrecorded data, compromising

Company
AMMAN PHARMACEUTICAL INDUSTRIES
Inspection date
August 15, 2023
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Francis Godwin (Director)
View Company Profile

ID · 0742ffc0-f974-4bfb-a725-339de65fe020

Violation Codes10
21 U.S.C. 351(a)(2)(B)21 CFR 21021 CFR 21121 CFR 211.42(c)(10)21 CFR 211.113(b)21 CFR 211.194(a)21 CFR 211.22(a)FD&C Act 501(a)(2)(B)FD&C Act 801(a)(3)21 U.S.C. 381(a)(3)

Full citation text and observation details available on the Dashboard.

Other documents for AMMAN PHARMACEUTICAL INDUSTRIES
  • 483 - 2023-08-15August 15, 2023
  • 483

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore AMMAN PHARMACEUTICAL INDUSTRIES
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.